 |
1 Product |  |
4 Diseases | | 1 Product |
|
0 Trials |  |
12 News |  |
- || Crataegutt (WS 1442) / Dr. Willmar Schwabe
Clinical, Journal: SAFETY AND EFFECTS OF CRATAEGUS EXTRACT WS 1442 AND NORDIC WALKING ON LIPID PROFILE AND ENDOTHELIAL FUNCTION: A RANDOMIZED, PARTIALLY BLINDED PILOT STUDY IN OVERWEIGHT VOLUNTEERS. (Pubmed Central) - Jul 21, 2020
All adverse events were unrelated or improbably related to treatment. In conclusion, WS 1442 and exercise training were safe and showed beneficial effects on endothelial function and lipid profile in overweight but otherwise healthy volunteers; exercise capacity improved only by Nordic walking.
- | Crataegutt (WS 1442) / Dr. Willmar Schwabe
Preclinical, Journal: Hawthorn revisited: time- and dose-dependent cardioprotective action of WS-1442 special extract in the reperfusion-induced arrhythmia model in rats in vivo. (Pubmed Central) - Jan 24, 2020
It was expressed by mortality index reduction, decrease in the incidence and duration of severe ventricular arrhythmias and decline in the total amount of creatine kinase. Analyzed data coming from a model of reperfusion-induced arrhythmias in rats suggests that standardized WS-1442 extract is a potent cardioprotective agent whose action depends on both dose and intake time.
- | Crataegutt (WS 1442) / Dr. Willmar Schwabe
Journal: Crataegus Extract WS®1442 Stimulates Cardiomyogenesis and Angiogenesis From Stem Cells: A Possible New Pharmacology for Hawthorn? (Pubmed Central) - Dec 22, 2019
The quantified Crataegus extract WS1442 stimulated cardiomyogenesis from murine and human embryonic stem cells (ESCs)...However, the in vivo relevance of this new pharmacological activity of Crataegus spp. remains to be investigated and active ingredients from bioactive fractions will have to be further characterized.
- | Crataegutt (WS 1442) / Dr. Willmar Schwabe
Journal: Crataegus Special Extract WS 1442 Effects on eNOS and microRNA 155. (Pubmed Central) - Nov 3, 2018
Surprisingly, WS 1442 increased miR-155 expression; however, WS 1442 mitigated the overall negative effect of miR-155 on decreasing eNOS expression by increasing expression of phosphorylated eNOS and resulting in an increase in NO concentrations. In the setting where miR-155 may be expressed, WS 1442 may offer vascular protection by increasing the expression of phosphorylated eNOS.
- || Crataegutt (WS 1442) / Dr. Willmar Schwabe
Trial primary completion date: WS (clinicaltrials.gov) - May 12, 2014
P1, N=60, Completed, Sponsor: Dr. Willmar Schwabe GmbH & Co. KG
In the setting where miR-155 may be expressed, WS 1442 may offer vascular protection by increasing the expression of phosphorylated eNOS. Trial primary completion date: Mar 2011 --> Sep 2010
- ||| Crataegutt (WS 1442) / Dr. Willmar Schwabe
Trial completion: WS (clinicaltrials.gov) - May 12, 2014
P1, N=60, Completed, Sponsor: Dr. Willmar Schwabe GmbH & Co. KG
Trial primary completion date: Mar 2011 --> Sep 2010 Active, not recruiting --> Completed